Treats hypertension. ANDA 77606, held by Aurobindo Pharma. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 77606 (Lisinopril and Hydrochlorothiazide), held by Aurobindo Pharma, was first approved by FDA on Mar 14, 2006, with 14 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lisinopril and Hydrochlorothiazide Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 14, 2006 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Aug 20, 2020 | Supplement 27Labeling · Standard review | Approved | None posted |
| Jul 16, 2020 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jul 16, 2020 | Supplement 23Labeling · Standard review | Approved | None posted |
| Nov 18, 2015 | Supplement 18Labeling · Standard review | Approved | None posted |
| Nov 18, 2015 | Supplement 19Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 9Labeling | Approved | None posted |
| Feb 26, 2014 | Supplement 11Labeling | Approved | None posted |
| Feb 26, 2014 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 15Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jan 18, 2011 | Supplement 6Labeling | Approved | None posted |
| Feb 6, 2007 | Supplement 1Labeling | Approved | None posted |
| Mar 14, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters